WHO issues first global guidelines for treating childhood obesity

The World Health Organization on Tuesday issued its first global clinical guidelines for managing obesity in children and adolescents, telling doctors and health systems worldwide that structured changes to diet, physical activity and behavior should remain the primary treatment for children under 10, while medication and surgery should be considered for older adolescents only after supervised lifestyle programs have failed.

The guidelines, published by WHO's nutrition and food safety department, mark the agency's first attempt to set a single clinical standard for treating obesity in young people, an area where national guidance has varied widely and, in many countries, has not existed at all. They arrive ten months after WHO issued its first-ever guidance recommending GLP-1 drugs such as semaglutide and tirzepatide for some adults with obesity, a recommendation the new pediatric guidelines deliberately do not extend to young children.

The Scale of the Problem

WHO estimates that 170 million children and adolescents between the ages of 5 and 19 were living with obesity in 2024, split roughly between 70 million children aged 5 to 9 and 100 million adolescents aged 10 to 19. The agency says obesity prevalence in that age group has quadrupled since 1990, rising from 2 percent to 8 percent of the population, a trend WHO's broader fact sheet on obesity and overweight traces back decades across both low- and middle-income and wealthier countries.

The Stakes Beyond Any One Child

WHO frames childhood obesity as a problem with consequences well beyond any single child's health. The agency's obesity and overweight fact sheet projects that the global economic burden of overweight and obesity across all ages will reach $3 trillion a year by 2030 and more than $18 trillion a year by 2060, a cost driven largely by treating diabetes, cardiovascular disease and other weight-related conditions as today's children grow into adults. WHO notes that children with obesity are very likely to carry it into adulthood, which the agency cites as one reason the new guidelines emphasize early, sustained intervention over a one-time treatment.

The psychosocial toll is treated as seriously as the physical one. WHO describes childhood and adolescent obesity as carrying effects that extend into school performance and quality of life, compounded by stigma, discrimination and bullying — a framing that runs through the new guidelines' emphasis on family-centered care rather than treating weight loss as an isolated medical outcome.

Alongside the clinical guidelines, WHO continues to push governments toward policies aimed at preventing childhood obesity before it starts, including restricting the marketing of foods high in sugar, salt and fat to children and teenagers, and pursuing broader fiscal and regulatory measures meant to make healthier food environments the default rather than the exception. Those prevention-focused recommendations sit outside the new clinical guidelines but are frequently cited by WHO in the same breath, reflecting the agency's view that treatment guidance alone will not reverse a trend it says has quadrupled since 1990.

Two Age Groups, Two Different Standards

The guidelines, developed over several years through WHO's standard process of evidence review and a public comment period, split recommendations sharply by age:

• For children younger than 10, WHO issues a strong recommendation against pharmacological treatment, bariatric surgery or weight-loss devices, regardless of severity.
• For adolescents aged 10 to 19, structured dietary, physical-activity and behavioral interventions remain the first-line approach, with digital health tools conditionally recommended only under parental supervision.
• Approved weight-loss medicines may be considered for adolescents only after a supervised, multimodal lifestyle program has not produced the desired results.
• Bariatric surgery may be considered for adolescents with severe obesity and associated complications, such as type 2 diabetes or hypertension, under strict conditions and only once lifestyle measures have been tried.

The approach contrasts with WHO's December 2025 guideline for adults, published in JAMA, which conditionally endorsed long-term use of GLP-1 therapies — including semaglutide, tirzepatide and liraglutide — for adults with a body mass index of 30 or higher, paired with intensive behavioral support. No such endorsement appears in the new pediatric guidance, which treats medication as a later-stage option for adolescents only, and not at all for younger children.

A Family-Centered, Mental-Health-Aware Approach

WHO officials framed the guidelines as an attempt to move pediatric obesity care away from a narrow focus on weight loss and toward a broader, person-centered model that accounts for stigma, bullying and the mental-health toll of obesity on young people, alongside physical risks such as type 2 diabetes and cardiovascular disease.

"The foundation of obesity care for children and adolescents is not medicine or surgery, but access to comprehensive support that enables healthy eating, physical activity and sustainable behaviour change," said Dr. Luz María De Regil, WHO's director of nutrition and food safety.

The guidelines call for family-engaged treatment strategies and long-term follow-up rather than one-time interventions, reflecting WHO's broader position, laid out in the development process documented on its guideline-development page, that obesity in children is a chronic condition requiring sustained primary-care management rather than a problem to be solved with a single prescription or procedure.

Reaction and What Comes Next

The announcement was distributed globally by wire services within hours; an Agence France-Presse account of the guidelines, carried under the headline "WHO says no obesity drugs, surgery for under-10s" in outlets including Kenya's Citizen Digital, confirmed the core recommendations and statistics in WHO's release. WHO's earlier guideline recommending GLP-1 drugs for some adults, issued in December 2025, was explicitly framed as "conditional," citing limited long-term safety data — a caution now echoed even more strongly in the new pediatric guidance's near-total restriction on drugs and surgery for the youngest children.

WHO guidelines are not binding on national governments, but the agency's past guidance on child health has historically served as a default clinical standard in countries without the resources to develop their own pediatric obesity protocols, and as a benchmark that professional medical societies in wealthier countries often weigh against their own existing guidance. WHO has not announced a timetable for revisiting the recommendations, but officials indicated the guidelines will be reviewed as longer-term evidence accumulates on the safety and effectiveness of weight-loss medications and surgery in adolescents.